PHARM.ASPHARM.ASAMS
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank79
3Y CAGR-7.1%
5Y CAGR+72.4%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-7.1%/yr
Quarterly compound
5Y CAGR
+72.4%/yr
Recent deceleration
Percentile
P79
Within normal range
vs 5Y Ago
15.2x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 172.72% |
| Q2 2025 | 4961.64% |
| Q1 2025 | -97.51% |
| Q4 2024 | -4.22% |
| Q3 2024 | 173.95% |
| Q2 2024 | -36.04% |
| Q1 2024 | -179.48% |
| Q4 2023 | 245.42% |
| Q3 2023 | 136.66% |
| Q2 2023 | 57.77% |
| Q1 2023 | -501.57% |
| Q4 2022 | -55.03% |
| Q3 2022 | 215.56% |
| Q2 2022 | 556.49% |
| Q1 2022 | -95.53% |
| Q4 2021 | 0.00% |
| Q2 2021 | 36.58% |
| Q1 2021 | -74.83% |
| Q4 2020 | 46.32% |
| Q3 2020 | -21.86% |
| Q2 2020 | 11.35% |
| Q1 2020 | -6.51% |
| Q4 2019 | -1.66% |
| Q3 2019 | 34.79% |
| Q2 2019 | 53.92% |
| Q1 2019 | -29.74% |
| Q4 2018 | -16.86% |
| Q3 2018 | 56.63% |
| Q2 2018 | 1133.50% |
| Q1 2018 | -103.47% |
| Q4 2017 | 107.91% |
| Q3 2017 | 3384.57% |
| Q2 2017 | 108.96% |
| Q1 2017 | -277.78% |
| Q4 2016 | 175.40% |
| Q3 2016 | 36.92% |
| Q2 2016 | -87.06% |
| Q1 2016 | 1.41% |
| Q4 2015 | 29.99% |
| Q3 2015 | 10.48% |